Actively Recruiting

Phase Not Applicable
Age: 19Years +
All Genders
NCT07267793

Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage

Led by DALIM TISSEN Co., Ltd. · Updated on 2026-01-20

194

Participants Needed

5

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.

CONDITIONS

Official Title

Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 19 years and older
  • Diagnosed with unilateral or bilateral knee osteoarthritis based on American College of Rheumatology criteria with at least three of these: age 50 or older, morning stiffness under 30 minutes, crepitus on motion, bony tenderness, bony enlargement, no palpable warmth
  • Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months before screening or at screening
  • Weight-bearing pain score of 40 mm or higher on a 100-mm visual scale in at least one knee at screening
  • Able to walk without assistive devices, or if using a walking aid routinely for the past 6 months, able to continue using the same device throughout the study
  • Able to understand and complete assessment questionnaires
  • Willing and able to provide written informed consent
Not Eligible

You will not qualify if you...

  • Body mass index of 32 kg/m2 or higher
  • Chronic inflammatory joint diseases such as rheumatoid arthritis
  • Inflammatory joint diseases like septic arthritis
  • Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic diseases
  • Painful musculoskeletal conditions such as Sudeck's atrophy, Paget's disease, or herniated disc
  • Severe osteoarthritis in other joints that may affect knee pain evaluation
  • Radiographic evidence of definite loss of patellofemoral joint space
  • Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
  • History of serious heart disease or uncontrolled high blood pressure despite treatment
  • History of autoimmune disease
  • Active infection needing parenteral antibiotics
  • History of psychiatric disorder or epilepsy
  • Cancer diagnosis within 5 years before screening
  • Uncontrolled diabetes with HbA1c over 7%
  • Surgery on target knee within 1 year
  • Intra-articular corticosteroid injection into target knee within 12 weeks
  • Systemic corticosteroid use within 4 weeks
  • Surgery or radiation therapy to knee within 12 weeks or not fully recovered
  • Immunosuppressive therapy within 6 weeks
  • Intra-articular injections like hyaluronic acid into knee within 6 months
  • Use of prohibited medications including certain anticoagulants and psychoactive drugs
  • History or planned cell or gene therapy to target joint
  • Abnormal lab values for liver or kidney function at screening
  • Engaged in high-intensity exercise that may affect knee joint
  • Skin disease at injection site or unsuitable injection site
  • Ligament instability of grade II or higher in target knee
  • Known allergy to study product or components
  • Pregnant or breastfeeding women
  • Women or men of childbearing potential unwilling to use contraception
  • Participation in another clinical trial within 4 weeks
  • Cognitive impairment or dementia preventing consent
  • Any condition making participation unsuitable by investigator judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Seoul National University Bundang Hospital

Seongnam-si, Bundang-gu, South Korea, 13620

Actively Recruiting

2

CHA Bundang Medical Center

Seoul, Bundang-gu, South Korea, 13496

Actively Recruiting

3

The Catholic University of Korea Eunpyeong St. Mary's Hospital

Seoul, Eunpyeong-gu, South Korea, 03312

Actively Recruiting

4

Gachon University Gil Hospital

Seoul, Namdong-gu, South Korea, 21565

Actively Recruiting

5

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, Seochogu, South Korea, 06591

Actively Recruiting

Loading map...

Research Team

H

Hyunjin Bae Dream CIS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here